Form 4: Apogee Therapeutics CEO Sells 40,000 Shares

Apogee Therapeutics' CEO, Michael Henderson, sold 40,000 shares of common stock for approximately $75.01 per share under a pre-arranged trading plan.

Summary

• Michael Thomas Henderson, Chief Executive Officer and Director of Apogee Therapeutics, Inc. (APGE), sold 40,000 shares of the company's common stock.
• The transaction occurred on December 4, 2025, at a weighted average price of $75.01 per share.
• The shares were sold in multiple transactions with prices ranging from $75.00 to $75.24, inclusive.
• This sale was executed pursuant to a Rule 10b5-1 trading plan that was adopted on August 13, 2025.
• Following this transaction, Michael Henderson beneficially owns 1,232,987 shares of Apogee Therapeutics common stock.

Sentiment

Score: 5

Explanation: A neutral score. While insider selling can be perceived negatively, the transaction was executed under a pre-arranged 10b5-1 plan, which mitigates concerns about opportunistic selling based on non-public information. It's a routine disclosure for planned liquidity events.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating it was a scheduled liquidity event and not a discretionary sale based on new, non-public information.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the insider's direct stake in the company.

Risks

• Potential negative market perception due to insider selling, which could put downward pressure on the stock price, despite the pre-planned nature of the transaction.

Future Outlook

NA

Industry Context

This Form 4 filing reports an insider transaction and does not provide specific details to analyze broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: May view the sale as a slight negative signal, though the 10b5-1 plan mitigates this. It reduces the CEO's direct ownership percentage.

Next Steps

• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the range upon request to the Issuer, any security holder, or the SEC staff.

Key Dates

Recommendation

The sale by the CEO, while significant in volume, was conducted under a pre-arranged 10b5-1 plan, which suggests it's a planned liquidity event rather than a reaction to new, negative company developments. This mitigates the typical negative signal of insider selling. Given the lack of other financial or operational details in this Form 4, a 'hold' recommendation is appropriate, awaiting further company disclosures for a more comprehensive assessment.

Keywords

Apogee Therapeutics, APGE, Michael Henderson, CEO, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Beneficial Ownership